The median time before the disease worsened was 9.6 months for those getting Kadcyla, compared with 6.4 months for those getting the other drugs.
It will take some months for those figures to emerge, he added.
I had been training for 18 months for those games and he could have proved a distraction.
Military service, much maligned by young Italians, lasts for 10 months for those not entering civil service.
Progression-free survival in melanoma (in other words, the amount of time during which a patient's cancer did not become worse) was 6.9 months for those on Opdivo alone and 2.9 months for those taking only Yervoy.
The median time that women lived before their cancer worsened was 12.4 months for those who got Avastin compared with 8.4 months for those who received only the two other drugs.
That was significantly longer than the 12.4 months for those who received a placebo, Herceptin and docetaxel.
Their time on benefits is limited to one year, or 18 months for those older than 55.
The patients getting Kadcyla lived a median of 30.9 months, compared with 25.1 months for those getting the two pills.
Patients who took it along with standard chemotherapy survived for a median of 12.3 months, compared with 10.3 months for those getting only chemotherapy.
In the trial, patients who received Nexavar lived a median of 10.7 months, compared with 7.9 months for those who received a placebo.
